Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cactin, encoded by the CACTIN gene, is a spliceosome C complex subunit involved in the facilitation of pre-mRNA splicing, including the excision of specific introns and the regulation of splicing for important cell cycle genes such as CDCA5 (Sororin)[1][2]. Cactin plays a regulatory role in the innate immune system as a negative regulator of several pro-inflammatory pathways, including those mediated by Toll-like receptors, interferon regulatory factors (IRFs), and the canonical NF-κB signaling pathway[1][2][5]. This protein is localized in the cytosol and nuclear speckles of cells, with highest expression observed in testis and spleen, and is conserved across vertebrates, plants, and fungi[1][2]. Originally identified as a renal carcinoma antigen, cactin has been primarily studied for its roles in RNA binding, immune modulation, and was first described in Drosophila[1][2][5]. There are currently no drugs, established biomarkers, or specific safety concerns directly associated with cactin as a therapeutic target, and it is not considered a classical drug target such as a receptor, enzyme, or transporter[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cactin, spliceosome C complex subunit (CACTIN).